Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

    Recruiting

    4 1 1
    Austria Belgium Bulgaria Czechia Denmark France +9
  • Study of Different Dosing Schedules of Osimertinib in Patients with EGFR Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium The Netherlands
  • Study of subcutaneous nivolumab with ipilimumab and chemotherapy in previously untreated patients with metastatic or recurrent non-small cell lung cancer

    Recruiting

    2 1 1 1
    France Greece Italy Poland Romania
  • Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    Austria Belgium Bulgaria Croatia France Germany +9
  • Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

    Recruiting

    4 1 1 1
    Belgium Bulgaria France Germany Hungary Italy +3
  • Study of ABBV-400 and Budigalimab for Adults with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

    Recruiting

    1 1 1 1
    Belgium France Germany Italy Poland Romania +1
  • Study on the Safety and Effects of STX-241 for Patients with Advanced Non-Small Cell Lung Cancer Resistant to EGFR Inhibitors

    Recruiting

    2 1 1
    Investigated Drugs:
    France Germany The Netherlands Spain
  • Study of Durvalumab, Tremelimumab, Chemotherapy, and Radiotherapy for Patients with Newly Diagnosed Non-Small Cell Lung Cancer with Limited Spread

    Recruiting

    2 1 1 1
    Investigated Drugs:
    Italy The Netherlands Spain
  • Study on Long-Term Safety of Trastuzumab Deruxtecan for Patients with Advanced HER2-Positive or HER2-Mutated Solid Tumors

    Recruiting

    3 1 1
    Investigated Drugs:
    Belgium France Italy Spain
  • Study Comparing MK-2870 and Pembrolizumab Combination to Pembrolizumab Alone for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Czechia Denmark France Germany Italy The Netherlands +3